Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canagliflozin monotherapy versus placebo in adults with type 2 diabetes mellitus inadequately controlled with diet and exercise
2009-015883-32Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of canagliflozin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Change in hemoglobin A1c. Started Dec 2009; status: completed.
02
Drugs
canagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2009-015883-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015883-32.